ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Designer Solid Self-Emulsifying Nanovaccines Enable Dual Modulation of Dendritic Cells and T Cells for Potent Antitumor Immunity.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanoparticle-Enabled Modulation of the Bone Immune Microenvironment for Enhanced Regeneration.Bioengineering (Basel, Switzerland) · 2026Review
- Review
- Acidic-responsive nano liposomes potentiate in situ dual immunotherapy on lung cancer by codelivering antagonistic peptide and agonist.International journal of pharmaceutics: X · 2026Article
- Designer Solid Self-Emulsifying Nanovaccines Enable Dual Modulation of Dendritic Cells and T Cells for Potent Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Peptide-based cancer vaccines offer favorable safety and stability profiles but are limited by rapid clearance and poor immunogenicity. Here, a ≈20 nm solid self-emulsifying (SSE) nanovaccine platform that co-delivers peptide antigens and an oligonucleotide adjuvant containing the 5'-C-phosphate-G-3' (CpG) motif is reported. This formulation elicits T-cell responses 40 fold higher than those of conventional emulsified vaccines and even achieves complete tumor regression at low doses. Apolipoprotein E (ApoE) adsorbed on SSE vaccines enhances lymph node targeting and dendritic cell internalization. Furthermore, SSE is internalized by T cells and promotes lipid raft formation, thereby further sensitizing T cells to activation. These findings reveal a dual mechanism of immune regulation through the simultaneous engagement of dendritic cells and T cells. The SSE platform offers a clinically translatable strategy for potent cancer immunotherapy and provides mechanistic insights into nanoparticle-immune cell interactions that may guide the design of next-generation nanovaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.